
handle: 10261/74600
[ES] La invención se relaciona con un método para el tratamiento de enfermedades neurodegenerativas y, en particular, de la enfermedad de Huntington, mediante el uso de inhibidores de la proteína DREAM y, en particular, de distintas moléculas de la familia de las glinidas como la Repaglinida.
[FR] L'invention concerne une méthode de traitement de maladies neurodégénératives et, en particulier, de la maladie de Huntington, au moyen de l'utilisation d'inhibiteurs de la protéine DREAM et, en particulier, de molécules distinctes de la famille des glinides, telles que la Répaglinide.
[EN] The invention relates to a method for treating neurodegenerative disorders and, in particular, Huntington's disease, by means of the use of DREAM protein inhibitors and, in particular, of different molecules from the glinide family, such as Repaglinide.
Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Consejo Superior de Investigaciones Científicas, Fundació privada Centre de Regulació Genómica (CRG), Fundación CIEN
A2 Solicitud de patente sin informe sobre el estado de la técnica
Peer reviewed
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
